KPTI News and Press, Karyopharm Therapeutics Inc. From 05/12/22

The following slide deck was published by Karyopharm Therapeutics Inc. in conjunction with their 2022 Q1 earnings call. For further details see: Karyopharm Therapeutics Inc. 2022 Q1 - Results - Earnings Call Presentation

Karyopharm Announces XPOVIO® (selinexor) Data to be Presented at the European Hematology Association 2022 Hybrid Congress PR Newswire NEWTON, Mass. , May 12, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (NASDAQ: KPTI), a commercial-stage pharmac...

Karyopharm to Participate at the 2022 RBC Capital Markets Global Healthcare Conference PR Newswire NEWTON, Mass. , May 10, 2022 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer...

Image source: The Motley Fool. Karyopharm Therapeutics (NASDAQ: KPTI) Q1 2022 Earnings Call May 05, 2022 , 8:30 a.m. ET Operator Continue reading For further details see: Karyopharm Therapeutics (KPTI) Q1 2022 Earnings Call Transcript

Karyopharm Therapeutics, Inc. (KPTI) Q1 2022 Earnings Conference Call May 05, 2022, 08:30 ET Company Participants Elhan Webb - SVP, IR Richard Paulson - President, CEO & Director Sohanya Cheng - EVP & Chief Commercial Officer Michael Mason - EVP, CFO & Treasurer Reshma Rangwala - ...

KPTI has been devastated by the SIENDO trial failure. The next trial's data will be read out 2 years later. Until then, I see little upside for the stock. For further details see: Karyopharm: Another 2 Year Wait For Data

Karyopharm Therapeutics press release (NASDAQ:KPTI): Q1 GAAP EPS of -$0.53 beats by $0.14. Revenue of $47.67M (+104.9% Y/Y) beats by $13.26M. Based on its current operating plans, Karyopharm reaffirms the following for full year 2022: XPOVIO net product revenue to be in the range of $135 mill...

Karyopharm Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress PR Newswire – Achieved First Quarter 2022 Net Revenues of $47.7 Million , Up 105% Versus First Quarter 2021, Including $19.4 Million License Revenues from ...

Karyopharm Therapeutics (NASDAQ:KPTI) is scheduled to announce Q1 earnings results on Thursday, May 5th, before market open. The consensus EPS Estimate is -$0.62 and the consensus Revenue Estimate is $34.41M (+47.9% Y/Y). Over the last 3 months, EPS estimates have seen 3 upward revisions and ...

AAWW,ABEV,ABUS,ACIW,ADNT,ADT,AGIO,ALDX,ALE,AMCX,AMR,APD,APO,APTV,ARGX,ARW,AUTL,AVEO,BALY,BCE,BCRX,OTCQX:BDRBF,BDX,BERY,BFLY,BLD,BLL,OTC:BLRDF,BUD,BXRX,CAH,CARS,CBRE,CCJ,CCOI,CCRD,CIM,CIO,CMRE,CNCE,CNSL,COMM,COP,CROX,CTHR,CWEN,D,DBRG,DDOG,DEN,DFIN,OTCQX:DLAKF,DLX,DNOW,DTM,OTCQX:EDVMF,ENG,EPAM,...